The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Management characterized the first quarter as meeting internal expectations, providing a stable foundation for the multi-year recovery plan.

Performance attribution for the quarter was driven by membership growth performing as expected and early medical cost indicators running in line with or better than guidance.

The company is shifting focus to the 2027 bid cycle with a primary objective of returning to a sustainable individual Medicare Advantage margin of at least 3% by 2028.

Strategic positioning emphasizes member retention as the second priority, using data-driven benefit adjustments to minimize churn while meeting margin targets.

Operational efficiency is being driven by a centralized transformation office that provides surge resources and tracks long-term strategic initiatives.

Clinical excellence efforts resulted in identifying chronic conditions faster for new members, leading to a 5% improvement in HEDIS gap closure pace per member.

CenterWell growth was supported by both Humana membership tailwinds and agnostic expansion, including the acquisition of Max Health to reach new markets.

Humana expects to double individual Medicare Advantage margins in 2026, adjusted for Stars, as a key milestone toward 2028 targets.

The 2027 bidding strategy assumes that medical cost trend will continue to outpace program funding, necessitating benefit and geographic adjustments.

Management expressed confidence in returning to top-quartile Stars results for the 2028 bonus year, though industry thresholds remain an October uncertainty.

Capital allocation will prioritize balance sheet efficiency, with plans to pursue non-core asset divestitures to fund strategic acquisitions over the coming months.

The funding plan for 2027 and 2028 includes approximately $1 billion to $1.5 billion in potential cash obligations related to Welsh Carson put options.

IBNR reserves grew 35% sequentially, significantly outpacing membership growth, which management described as a prudent approach given early-year uncertainty.

The Insurance segment is undergoing a leadership transition, with George Renaudin retiring in June 2026 and Aaron Martin assuming day-to-day management immediately.

CenterWell's first-quarter operating cost ratio was impacted by non-recurring items, including skin substitute costs in the ACO REACH program and integration costs for Max Health.

The company successfully mitigated over $3 billion in capital contribution requirements for 2026 through subsidiary reinsurance and legal entity optimization.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management confirmed that returning to a 3% margin by 2028 is the 'Priority Number 1' that constrains all other bidding decisions.

They will use a market-by-market approach to adjust benefits, focusing on retaining members by protecting the benefits they value most.

Growth is currently a 'distant third priority' compared to margin recovery and member retention.

The gap between CMS funding and medical cost trend is explicitly larger heading into the 2027 bid season than it was a year ago.

While operational transformation provides more levers than in previous years, management signaled that benefit cuts remain a necessary tool to bridge this funding gap.

Management is utilizing more disciplined, real-time monitoring of claims inventory and front-end anomalies to identify 'hotspots' faster.

Data through April shows hospital admits per thousand and pharmacy claims are performing in line with or better than the conservative assumptions in the 2026 guidance.

A decision on the June call option for clinic cohorts will be made mid-year, balancing strategic value against cash position.

If put options are exercised, the cash obligation is estimated at $1 billion to $1.5 billion in 2027, which is already factored into the company's funding plan.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.